An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States currently benefiting or who have benefited from treatment with gefitinib.

Trial Profile

An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States currently benefiting or who have benefited from treatment with gefitinib.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top